3-propyl-5-methylisoxazole | 26226-07-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-propyl-5-methylisoxazole
• 英文别名: 5-Methyl-3-propyl-isoxazol；5-methyl-3-propyl-isoxazole；5-Methyl-3-propyl-1,2-oxazole
• CAS: 26226-07-3
• 化学式: C₇H₁₁NO
• 分子量: 125.17
• InChiKey: ZYHSPHQOSBGAIT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-奎宁环酮 、 3-propyl-5-methylisoxazole 在 正丁基锂 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 1.75h， 生成
  参考文献：
  名称：

  Improving the Nicotinic Pharmacophore with a Series of (Isoxazole)methylene-1-azacyclic Compounds:  Synthesis, Structure−Activity Relationship, and Molecular Modeling

  摘要：

  A series of (isoxazole)methylene-1-azacyclic compounds was prepared. The compounds were tested for affinity to central nicotinic acetylcholine receptors (nAChRs) and central muscarinic receptors. The compounds covered a broad range of affinities for the nAChRs (IC50 = 0.32 to >1000 nM), with selectivities for the nAChRs over the muscarinic receptors in the range of 3-183. The high-affinity compound (Z)-26 (3-(4-methyl-5-isoxazolyl)methylene-1-azabicyclo-[2.2.2]octane, IC50 = 3.2 nM) having only one energy minimum was used as the reference structure in a computational study. This ligand has enabled definition of an important distance parameter, and the existence of this parameter was supported by showing that other potent nicotinic ligands (for example, nicotine and epibatidine) fit the model.

  DOI：

  10.1021/jm9910627
• 作为产物：
  描述：

  acetic acid 5-methyl-3-propyl-4,5-dihydro-isoxazol-5-yl ester 在 盐酸 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 3-propyl-5-methylisoxazole
  参考文献：
  名称：

  Improving the Nicotinic Pharmacophore with a Series of (Isoxazole)methylene-1-azacyclic Compounds:  Synthesis, Structure−Activity Relationship, and Molecular Modeling

  摘要：

  A series of (isoxazole)methylene-1-azacyclic compounds was prepared. The compounds were tested for affinity to central nicotinic acetylcholine receptors (nAChRs) and central muscarinic receptors. The compounds covered a broad range of affinities for the nAChRs (IC50 = 0.32 to >1000 nM), with selectivities for the nAChRs over the muscarinic receptors in the range of 3-183. The high-affinity compound (Z)-26 (3-(4-methyl-5-isoxazolyl)methylene-1-azabicyclo-[2.2.2]octane, IC50 = 3.2 nM) having only one energy minimum was used as the reference structure in a computational study. This ligand has enabled definition of an important distance parameter, and the existence of this parameter was supported by showing that other potent nicotinic ligands (for example, nicotine and epibatidine) fit the model.

  DOI：

  10.1021/jm9910627

文献信息

• FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS
  申请人：Corkey Britton Kenneth

  公开号：US20120289493A1

  公开（公告）日：2012-11-15

  The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein Q, R 1 , X 1 , X 2 , Y and R 2 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

  本公开涉及一类为钠通道抑制剂的化合物，以及它们在治疗各种疾病状态中的应用，包括心血管疾病和糖尿病。在特定实施例中，该化合物的结构由式I给出： 其中Q、R1、X1、X2、Y和R2如本文所述，以及制备和使用该化合物的方法，以及含有该化合物的药物组合物。
• [EN] 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS<br/>[FR] COMPOSÉS 1H-PYRAZOLO[4,3-D]PYRIMIDINE UTILES EN TANT QU'AGONISTES DU RÉCEPTEUR DE TYPE TOLL 7 (TLR7)
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2021154666A1

  公开（公告）日：2021-08-05

  Compounds according to formula I or II are useful as agonists of Toll-like receptor 7 (TLR7). (I) (II) Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.

  根据公式I或II合成的化合物可用作Toll样受体7（TLR7）的激动剂。这些化合物可用于癌症治疗，特别是与抗癌免疫疗法药物联合使用，或作为疫苗佐剂。
• [EN] BENZAMIDE AND NICOTINAMIDE COMPOUNDS AND METHODS OF USING SAME<br/>[FR] BENZAMIDE ET COMPOSÉS DE NICOTINAMIDE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：ONCOTARTIS INC

  公开号：WO2015100322A1

  公开（公告）日：2015-07-02

  The present disclosure provides benzamide and nicotinamide compounds and pharmaceutical uses of the compounds. The compounds can be used to treat, for example, cancers such hematopoietic cancers (e.g., leukemia). The preferred compounds of the invention contain a phenylethynyl moiety as well as an amine-based heterocyclyl or heteroaryl moiety attached to the benzamide or nicotinamide compound.

  本公开提供苯甲酰胺和烟酰胺化合物以及这些化合物的药用。这些化合物可用于治疗，例如，血液肿瘤等血液肿瘤（如白血病）。本发明的优选化合物包含苯乙炔基团以及连接到苯甲酰胺或烟酰胺化合物的胺基杂环基团或杂芳基团。
• Novel high affinity thiophene-based and furan-based kinase ligands
  申请人：Deng Yongqi

  公开号：US20070043045A1

  公开（公告）日：2007-02-22

  Inhibitors of cyclin dependent kinase 2, compositions including the inhibitors, and methods of using the inhibitors and inhibitor compositions are described. The inhibitors and compositions including them are useful for treating disease or disease symptoms. The invention also provides for methods of making CDK-2 inhibitor compounds, methods of inhibiting CDK-2, and methods for treating disease or disease symptoms.

  描述了抑制细胞周期依赖性激酶2（CDK-2）的抑制剂、包括这些抑制剂的组合物，以及使用这些抑制剂和抑制剂组合物的方法。这些抑制剂和包括它们的组合物对于治疗疾病或疾病症状是有用的。该发明还提供了制备CDK-2抑制剂化合物的方法、抑制CDK-2的方法，以及治疗疾病或疾病症状的方法。
• [EN] PYRAZOLE DERIVATIVES WHICH MODULATE STEAROYL-COA DESATURASE<br/>[FR] DÉRIVÉS DE PYRAZOLE QUI MODULENT LA STÉAROYL-COA DÉSATURASE
  申请人：NOVARTIS AG

  公开号：WO2011039358A1

  公开（公告）日：2011-04-07

  The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.

  本发明提供了能够调节硬脂酰辅酶A脱饱和酶活性的杂环衍生物。还涵盖了利用这些衍生物调节硬脂酰辅酶A脱饱和酶活性的方法以及包含这些衍生物的药物组合物。